Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients.
D000928:Antidepressive Agents / Q000009:adverse effects; D001714:Bipolar Disorder / Q000188:drug therapy*; D002395:Catecholamines / Q000378:metabolism; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000009:adverse effects*; D004298:Dopamine / Q000652:urine; D005059:Euphoria; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008781:Methyltyrosines / Q000494:pharmacology; D008875:Middle Aged; D010648:Phenylacetates / Q000134:cerebrospinal fluid / Q000652:urine; D010919:Placebos; D011596:Psychomotor Disorders / Q000139:chemically induced*; D012895:Sleep, REM / Q000187:drug effects; D013237:Stereoisomerism; D014793:Visual Cortex / Q000187:drug effects
D000928:Antidepressive Agents; D002395:Catecholamines; D006834:Hydrazines; D008781:Methyltyrosines; D010648:Phenylacetates; D010919:Placebos; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D004298:Dopamine